MX4684A - Clorohidrato de n,n-dimetil-1-(1-(4-clorofenil)ciclobutil)-3-metilbutilamina y proceso para su preparacion. - Google Patents

Clorohidrato de n,n-dimetil-1-(1-(4-clorofenil)ciclobutil)-3-metilbutilamina y proceso para su preparacion.

Info

Publication number
MX4684A
MX4684A MX468486A MX468486A MX4684A MX 4684 A MX4684 A MX 4684A MX 468486 A MX468486 A MX 468486A MX 468486 A MX468486 A MX 468486A MX 4684 A MX4684 A MX 4684A
Authority
MX
Mexico
Prior art keywords
chlorophenyl
dimethyl
cycllobutyl
chlorohydrate
preparation
Prior art date
Application number
MX468486A
Other languages
English (en)
Spanish (es)
Inventor
James Edward Jaffery
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10589895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX4684(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boots Co Plc filed Critical Boots Co Plc
Publication of MX4684A publication Critical patent/MX4684A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX468486A 1985-12-17 1986-12-16 Clorohidrato de n,n-dimetil-1-(1-(4-clorofenil)ciclobutil)-3-metilbutilamina y proceso para su preparacion. MX4684A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858531071A GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound

Publications (1)

Publication Number Publication Date
MX4684A true MX4684A (es) 1993-12-01

Family

ID=10589895

Family Applications (1)

Application Number Title Priority Date Filing Date
MX468486A MX4684A (es) 1985-12-17 1986-12-16 Clorohidrato de n,n-dimetil-1-(1-(4-clorofenil)ciclobutil)-3-metilbutilamina y proceso para su preparacion.

Country Status (34)

Country Link
US (2) US4929629A (enExample)
EP (1) EP0230742B1 (enExample)
JP (1) JPS62155240A (enExample)
KR (1) KR940008913B1 (enExample)
CN (1) CN1016245B (enExample)
AT (1) ATE56942T1 (enExample)
AU (1) AU601167B2 (enExample)
CA (1) CA1266278A (enExample)
CS (1) CS259545B2 (enExample)
DD (1) DD263050A5 (enExample)
DE (1) DE3674570D1 (enExample)
DK (1) DK170770B1 (enExample)
EG (1) EG17770A (enExample)
ES (1) ES2018163T4 (enExample)
FI (1) FI90413C (enExample)
GB (1) GB8531071D0 (enExample)
GE (1) GEP19970812B (enExample)
GR (1) GR3001069T3 (enExample)
HU (1) HU201901B (enExample)
IE (1) IE59429B1 (enExample)
IL (1) IL80934A (enExample)
IN (1) IN163129B (enExample)
LU (1) LU90865I2 (enExample)
MX (1) MX4684A (enExample)
NL (1) NL300065I1 (enExample)
NO (2) NO165540C (enExample)
NZ (1) NZ218578A (enExample)
PH (1) PH22481A (enExample)
PL (1) PL149519B1 (enExample)
PT (1) PT83958B (enExample)
SU (1) SU1443796A3 (enExample)
UA (1) UA7206A1 (enExample)
YU (1) YU46033B (enExample)
ZA (1) ZA869078B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
CA2139000A1 (en) * 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
AU4542893A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE4443891A1 (de) 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
WO2000043002A1 (en) * 1999-01-20 2000-07-27 Knoll Pharmaceutical Company Method to aid smoking cessation
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
PL351958A1 (en) * 1999-03-19 2003-07-14 Knoll Gmbh Treatment of some tumours associated with gain in weight
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
AU3896900A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of pain
CA2366660A1 (en) * 1999-03-19 2000-09-28 Carl M. Mendel Treatment of osteoarthritis
WO2000056312A1 (en) 1999-03-19 2000-09-28 Knoll Gmbh Treatment of pulmonary hypertension
US6433020B1 (en) 1999-03-19 2002-08-13 Knoll Pharmaceutical Company Treatment of cardiovascular disease
US6376554B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Method of treating sexual dysfunction
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6441046B1 (en) 1999-03-19 2002-08-27 Abbott Gmbh & Co. Kg Control of metabolism
WO2000056319A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
AU3895300A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
HUP0200501A3 (en) * 1999-03-19 2004-03-29 Abbott Gmbh & Co Kg Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treating sleep apnoea
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
WO2002083631A1 (en) * 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
ATE486842T1 (de) * 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
MXPA05003355A (es) * 2002-10-05 2005-10-18 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende semihidrato de metansulfonato de sibutramina cristalino.
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
WO2006073292A1 (en) 2005-01-06 2006-07-13 Cj Corporation Inorganic acid salts of sibutramine
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
US20090203738A1 (en) * 2005-09-22 2009-08-13 Eisai R&D Management Co., Ltd. Pharmaceutical Composition for Treating Bulimia and Depression Arising from Bulimia
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AU2007219236B2 (en) * 2006-02-23 2012-06-21 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
MX2009002781A (es) 2006-09-15 2009-03-30 Reviva Pharmaceuticals Inc Sintesis, metodos de uso y composiciones de cicloalquilmetilaminas .
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
JP2010510201A (ja) * 2006-11-20 2010-04-02 グレンマーク・ファーマシューティカルズ・エスエー ステアリン酸ＣｏＡ脱飽和酵素阻害剤としてのアセチレン誘導体
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
WO2008124120A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
JP5530438B2 (ja) * 2008-08-06 2014-06-25 ファイザー・リミテッド Ｍｃ４作動薬としてのジアゼピンおよびジアゾカン化合物
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US8669380B2 (en) 2009-11-02 2014-03-11 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
EA201291384A1 (ru) 2010-07-06 2013-07-30 Астразенека Аб Терапевтические агенты 976
MX366925B (es) 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
EP2890370B1 (en) 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
CN110372522B (zh) * 2019-07-30 2020-10-02 南京工业大学 一种从含有戊二胺的固相中汽提回收戊二胺的方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
SE7600674L (sv) * 1975-02-05 1976-08-06 Rohm & Haas Fungicider
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB2115409B (en) * 1982-02-24 1985-08-07 Zyma Sa Novel crystal modifications of (+)-catechin
DK101683A (da) * 1982-03-12 1983-09-13 Duphar Int Res Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
PL263020A1 (en) 1988-05-12
DE3674570D1 (de) 1990-10-31
PT83958A (en) 1987-01-01
CS930586A2 (en) 1988-02-15
DK170770B1 (da) 1996-01-15
SU1443796A3 (ru) 1988-12-07
NO865093D0 (no) 1986-12-16
DK585786A (da) 1987-06-18
FI865030L (fi) 1987-06-18
HU201901B (en) 1991-01-28
HUT45964A (en) 1988-09-28
EG17770A (en) 1991-03-30
UA7206A1 (uk) 1995-06-30
AU601167B2 (en) 1990-09-06
EP0230742A1 (en) 1987-08-05
NO2005022I1 (no) 2005-10-03
DK585786D0 (da) 1986-12-05
KR870005961A (ko) 1987-07-08
EP0230742B1 (en) 1990-09-26
LU90865I2 (fr) 2002-02-18
NO865093L (no) 1987-06-18
PT83958B (pt) 1989-05-12
IE863102L (en) 1987-06-17
JPH0144176B2 (enExample) 1989-09-26
NL300065I1 (nl) 2001-12-01
YU205086A (en) 1987-12-31
ATE56942T1 (de) 1990-10-15
US4929629A (en) 1990-05-29
NZ218578A (en) 1989-04-26
NO165540B (no) 1990-11-19
PL149519B1 (en) 1990-02-28
CN86108547A (zh) 1987-08-19
IE59429B1 (en) 1994-02-23
FI90413C (fi) 1994-02-10
ZA869078B (en) 1987-07-29
ES2018163T4 (es) 2012-06-14
DD263050A5 (de) 1988-12-21
GEP19970812B (en) 1997-02-10
GB8531071D0 (en) 1986-01-29
IL80934A (en) 1990-07-26
JPS62155240A (ja) 1987-07-10
YU46033B (sh) 1992-12-21
CA1266278A (en) 1990-02-27
AU6644286A (en) 1987-06-18
IN163129B (enExample) 1988-08-13
GR3001069T3 (en) 1992-03-20
ES2018163B3 (es) 1991-04-01
CS259545B2 (en) 1988-10-14
FI90413B (fi) 1993-10-29
FI865030A0 (fi) 1986-12-10
KR940008913B1 (ko) 1994-09-28
US5068440A (en) 1991-11-26
PH22481A (en) 1988-09-12
CN1016245B (zh) 1992-04-15
NO165540C (no) 1991-02-27

Similar Documents

Publication Publication Date Title
NL300065I1 (nl) N,N-dimethyl-1Ä1-(4-chloorfenyl)cyclobutylÜ-3-methylbutylamine-hydrochloride, monohydraat en farmaceutische preparaten, die deze bevatten.
BR8502688A (pt) Granulo contendo substancia fisiologicamente ativa,processo para preparar o mesmo e processo para criar ruminantes
BR8603251A (pt) Clorossulfato de aluminio basico,processos para a preparacao do mesmo e para o tratamento de um meio aquoso
DK585886D0 (da) Immunstimulerende middel og anvendelse deraf
ITRM930752A0 (it) Cartuccia a perdere di orecchini per la foratura del lobo auricolare erelativi fermi integrata con morsetto di presa auricolare.
NO890187D0 (no) 2-(3,4-dihydroksyfenyl)etylaminer, deres fremstilling og anvendelse som farmasoeytika.
DE3862017D1 (de) Pharmazeutische zubereitung zur behandlung von tinea pedis.
NZ221596A (en) N-(2-(4-carboxymethoxyphenyl)-1-(r)-1-methylethyl)-2-(r)-2- hydroxy-2-(3-chlorophenyl)ethanamine optionally with the ss-isomer also, and pharmaceutical and veterinary uses
GB2184122B (en) N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
HUT41817A (en) Process for preparing p-/acyl-amino/-benzamides
PT82528B (pt) Processo para a preparacao de composicoes larvicidas contendo n-{{(4-clorofenil)amino}carbonil}-2,6-difluorobenzamida
GR3015373T3 (en) 2-Halogen-substituted N-indolyl sulfonic-acid amides, process for their preparation and their pharmaceutical use.
NL193316B (nl) Onverzadigde cycloalifatische verbindingen, en cosmetische en farmaceutische preparaten, die deze onverzadigde cycloalifatische verbindingen bevatten.
ES8201133A1 (es) Un procedimiento para la produccion de 1-(1-metiletil)amino-3-(4-alquiltio)-1-naftalenil-oxi-2-propanol.
ZA851953B (en) Arachidonic acid analogues,processes for their preparation and their use in medicine
NO873481D0 (no) Peptidpreparat, fremgangsmaate for dets fremstilling og anvendelse derav.
IT8721566V0 (it) Astuccio-contenitore per esposizione, vendita ed utilizzo di carta-modelli.